Nitrothiophene carboxamides, a novel narrow spectrum antibacterial series: Mechanism of action and Efficacy [Bugworks Res. Pvt. Ltd., a C-CAMP Startup]

You are here

COVID-19 Response: Local Logistics     National Effort

TitleNitrothiophene carboxamides, a novel narrow spectrum antibacterial series: Mechanism of action and Efficacy [Bugworks Res. Pvt. Ltd., a C-CAMP Startup]
Publication TypeJournal Article
Year of Publication2018
AuthorsP SHameed, Bharatham N, Katagihallimath N, Sharma S, Nandishaiah R, Shanbhag AP, Thomas T, Narjari R, Sarma M, Bhowmik P, Amar P, Ravishankar R, Jayaraman R, Muthan K, Subbiah R, Ramachandran V, Balasubramanian V, Datta S
JournalSci Rep
Volume8
Issue1
Pagination7263
Date Published2018 May 08
ISSN2045-2322
Abstract

The mechanism of efflux is a tour-de-force in the bacterial armoury that has thwarted the development of novel antibiotics. We report the discovery of a novel chemical series with potent antibacterial properties that was engineered to overcome efflux liability. Compounds liable to efflux specifically via the Resistance Nodulation and cell Division (RND) pump, AcrAB-TolC were chosen for a hit to lead progression. Using structure-based design, the compounds were optimised to lose their binding to the efflux pump, thereby making them potent on wild-type bacteria. We discovered these compounds to be pro-drugs that require activation in E. coli by specific bacterial nitroreductases NfsA and NfsB. Hit to lead chemistry led to the generation of compounds that were potent on wild-type and multi-drug resistant clinical isolates of E. coli, Shigella spp., and Salmonella spp. These compounds are bactericidal and efficacious in a mouse thigh infection model.

DOI10.1038/s41598-018-25407-7
Alternate JournalSci Rep
PubMed ID29740005